Pharmacokinetic Evaluation of Afamelanotide in Adolescent and Adult Patients with Erythropoietic Protoporphyria (EPP)

The primary objective of this study is to evaluate the **pharmacokinetics** of afamelanotide following its administration to adolescent and adult patients with **Erythropoietic Protoporphyria (EPP)**. Additionally, the study aims to determine the relative comparability of the pharmacokinetic profiles of afamelanotide between these two patient groups. Understanding the pharmacokinetics is clinically relevant as it provides insights into the absorption, distribution, metabolism, and excretion of the drug, which are crucial for optimizing dosing regimens and ensuring therapeutic efficacy and safety.

The secondary objective is to assess the safety and tolerability of afamelanotide in the same patient population. Evaluating safety and tolerability is essential to identify any adverse effects and to ensure that the treatment is well-tolerated by patients, thereby supporting its potential use in clinical practice.

The clinical trial involves a total of **28 participants** diagnosed with **Erythropoietic Protoporphyria (EPP)**, comprising both adolescent and adult patients. The study population includes 14 adolescents aged between 12 and 17 years and 14 adults aged between 18 and 70 years. Both male and female subjects are included in the trial. Participants were selected based on their ability to understand and sign the informed consent form, with parental or legal representative consent required for adolescent participants. They must also agree not to use any medications during the trial period and be able and willing to adhere to the protocol requirements. The trial population is characterized by a vulnerable group, given the inclusion of adolescents. No specific lifestyle considerations such as diet or physical activity are highlighted in the selection criteria.

The clinical trial is designed to evaluate the **pharmacokinetics** of **afamelanotide** in patients diagnosed with **Erythropoietic Protoporphyria (EPP)**. This study is structured as a randomized, double-blind, controlled trial, ensuring that neither the participants nor the researchers know who is receiving the treatment or placebo, thus minimizing bias. The trial is expected to commence on February 19, 2024, and conclude by July 26, 2024, with a total duration of approximately five months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on specific criteria, such as age and the ability to provide informed consent. The trial will include fourteen adult patients aged 18 to 70 years and fourteen adolescent patients aged 12 to 17 years. Participants must agree not to use any medications during the study period. Following the screening, eligible participants will receive the **SCENESSE 16 mg implant**, administered subcutaneously, and will be monitored for primary endpoints, including Cmax and AUC(0-t), to determine the drug's pharmacokinetic profile.

Throughout the trial, participants will attend follow-up visits to monitor their response to the treatment and ensure adherence to the protocol. These visits are crucial for collecting data on the drug's safety and efficacy. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to gather comprehensive data on the treatment's impact.

The expected length of participant involvement is aligned with the trial's overall duration, approximately five months. However, conditions such as adverse reactions, non-compliance with the study protocol, or withdrawal of consent may lead to early termination from the study. The trial's methodology and design are meticulously crafted to ensure the collection of reliable and valid data, contributing to the understanding of **afamelanotide**'s pharmacokinetics in the target population.

The clinical trial involves the administration of **SCENESSE 16 mg implant**, an experimental medication designed to evaluate its pharmacokinetics in patients with **Erythropoietic Protoporphyria (EPP)**. The active substance in SCENESSE is **afamelanotide**, a synthetic hormone classified under the ATC code D02BB02. The pharmaceutical form of the medication is an implant, which is administered subcutaneously. The implant contains 16 mg of afamelanotide and is produced by CLINUVEL EUROPE LIMITED. The trial aims to assess the pharmacokinetic profile of afamelanotide in both adolescent and adult patients with EPP, ensuring the comparability of the pharmacokinetic profiles across these age groups.

In this study, SCENESSE is the primary investigational product, and no additional non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatments, are specified. The administration of the implant is conducted subcutaneously, and the frequency of administration is determined by the study protocol, which is not detailed in the provided data. Participant compliance with the dosing schedule is monitored throughout the trial to ensure accurate assessment of the pharmacokinetics of afamelanotide. The trial does not involve a pediatric formulation, and the product is designated as an orphan drug, highlighting its use in treating a rare condition.

Efficacy in the clinical trial evaluating the pharmacokinetics of **afamelanotide** in patients with Erythropoietic Protoporphyria (EPP) will be assessed using specific primary endpoints. The primary endpoints include the maximum concentration (Cmax) and the area under the curve (AUC(0-t)) of afamelanotide. These parameters will provide insights into the drug's absorption and overall exposure in the body following administration. The trial aims to determine the pharmacokinetics of afamelanotide in both adolescent and adult EPP patients, as well as to compare the pharmacokinetic profiles between these two groups.